WVE Form 4: Aik Na Tan Receives Equity Awards with $8.105 Strike
Rhea-AI Filing Summary
Wave Life Sciences Ltd. (WVE) Director Aik Na Tan reported equity awards on 08/11/2025 under the company’s 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 25,400 restricted share units (RSUs) that vest 50% on the earlier of the 2026 annual general meeting or August 11, 2026 and 50% on the earlier of the 2027 annual general meeting or August 11, 2027. The reporting person was also granted a share option for 152,400 ordinary shares with an exercise price of $8.105, vesting 12.5% quarterly beginning August 11, 2025 over two years and expiring on 08/11/2030. After these reported transactions the form lists 40,388 ordinary shares and 152,400 derivative securities beneficially owned by the reporting person.
Positive
- Equity-based compensation aligns the director’s interests with long-term shareholders via RSUs and options
- Clear vesting schedules (50%/50% for RSUs; 12.5% quarterly for options) support retention and transparency
Negative
- Potential dilution of up to 177,800 shares if the 25,400 RSUs vest and 152,400 options are exercised
- RSUs granted at $0.00 increase outstanding share count without cash proceeds to the company
Insights
TL;DR: Routine director compensation disclosed: RSUs plus options create retention incentives without immediate cash transfer.
The Form 4 documents a standard non-employee director award: 25,400 RSUs and a 152,400-share option at an $8.105 exercise price. Vesting schedules are time-based and staggered, aligning the director’s interests with long-term shareholder value while delaying potential dilution until vesting/exercise. The expiration date of 08/11/2030 gives multi-year optionality. From a market-impact perspective, this filing is routine and informational for governance and share-capital monitoring.
TL;DR: Compensation follows disclosed policy; vesting structure supports retention but increases potential outstanding shares.
The awards were granted pursuant to the company’s 2025 Non-Employee Director Compensation Policy, with explicit vesting terms: RSUs vest in two equal installments tied to AGMs or calendar dates, and options vest quarterly at 12.5% increments over two years. These features indicate a focus on retention and alignment. The filing clearly discloses quantities, exercise price, vesting cadence, and expiration, meeting standard disclosure expectations for insider transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (right to buy) | 152,400 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 25,400 | $0.00 | -- |
Footnotes (1)
- The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2026 annual general meeting or August 11, 2026; and (ii) the earlier of the Company's 2027 annual general meeting or August 11, 2027. The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 11, 2025, through the two-year period following the grant date.
